Mouse Osteoprotegerin (OPG) ELISA Kit | OPG elisa kit

Mouse Osteoprotegerin (OPG) Mini Samples ELISA Kit

Cat. Num. AAA2708255

• Gene Names: Tnfrsf11b; Opg; TR1; OCIF
• Reactivity: Mouse
• Applications: ELISA
• Synonyms: Osteoprotegerin (OPG); Mouse Osteoprotegerin (OPG) Mini Samples ELISA Kit; Osteoprotegerin; TNFRSF11B; TNFRSF11-B; OCIF; OPG; TR1; Tumor Necrosis Factor Receptor Superfamily Member 11b; Osteoclastogenesis Inhibitory Factor; OPG elisa kit

• Reactivity: Mouse
• Specificity: This assay has high sensitivity and excellent specificity for detection of Mini Samples Osteoprotegerin (OPG).; No significant cross-reactivity or interference between Mini Samples Osteoprotegerin (OPG) and analogues was observed.
• Sequence Length: 401

• Applicable Applications for OPG elisa kit: ELISA (EIA)
• Assay Type: Double-antibody Sandwich
• Samples: Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
• Detection Range: 0.156-10ng/mL
• Sensitivity: The minimum detectable dose of this kit is typically less than 0.055ng/mL
• Precision: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Mini Samples Osteoprotegerin (OPG) were tested 20 times on one plate, respectively.; Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Mini Samples Osteoprotegerin (OPG) were tested on 3 different plates, 8 replicates in each plate.; CV(%) = SD/meanX100; Intra-Assay: CV<10%; Inter-Assay: CV<12%
• Test Principle: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mini Samples Osteoprotegerin (OPG). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Mini Samples Osteoprotegerin (OPG). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mini Samples Osteoprotegerin (OPG), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm +/- 10nm. The concentration of Mini Samples Osteoprotegerin (OPG) in the samples is then determined by comparing the O.D. of the samples to the standard curve.
• Preparation and Storage: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.; To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Typical Testing Data/Standard Curve (for reference only)

NCBI and Uniprot Product Information

• NCBI GI #: 113930716
• NCBI GeneID: 18383
• NCBI Accession #: NP_032790.3
• NCBI GenBank Nucleotide #: NP_032790.3
• UniProt Accession #: O08712
• NCBI Official Full Name: tumor necrosis factor receptor superfamily member 11B
• NCBI Official Synonym Full Names: tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)
• NCBI Official Symbol: Tnfrsf11b
• NCBI Official Synonym Symbols: Opg; TR1; OCIF
• NCBI Protein Information: tumor necrosis factor receptor superfamily member 11B
• UniProt Protein Name: Tumor necrosis factor receptor superfamily member 11B
• UniProt Gene Name: Tnfrsf11b
• UniProt Synonym Gene Names: Ocif; Opg

Uniprot Description

TNFRSF11B: Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD); also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast- mediated skeletal resorption, the disease can be fatal.

Protein type: Inhibitor; Secreted; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 15|15 D1

Cellular Component: extracellular space; integral to plasma membrane; proteinaceous extracellular matrix

Molecular Function: tumor necrosis factor receptor activity

Biological Process: extracellular matrix organization and biogenesis; immune response; inflammatory response; negative regulation of bone resorption; negative regulation of odontogenesis of dentine-containing teeth; positive regulation of MAPKKK cascade; regulation of apoptosis; regulation of cell proliferation; response to lipopolysaccharide